Skip to Content

Zelnate

This page contains information on Zelnate for veterinary use.
The information provided typically includes the following:
  • Zelnate Indications
  • Warnings and cautions for Zelnate
  • Direction and dosage information for Zelnate

Zelnate

This treatment applies to the following species:
Manufacturer: Bayer Animal Health

DNA Immunostimulant

For Intramuscular Administration to Cattle

02293

FOR VETERINARY USE ONLY

READ IN FULL

Description

ZELNATE™ is a bacterial-produced plasmid DNA with a liposome carrier that stimulates the innate immune system in cattle. The innate immune system has been shown to provide a potent, rapid, nonspecific, protective response to infectious agents, such as those that can lead to Bovine Respiratory Disease (BRD). BRD is a serious condition that commonly causes lung lesions, reduced lung capacity and mortality.

The freeze-dried (desiccate) product is packaged with two different sterile diluents. The First Sterile Rehydrator (vial 1) is used to reconstitute the desiccate cake (vial 2), and then transferred to the Final Sterile Solution (vial 3) to achieve the proper concentration for administration.

INDICATION

ZELNATE™ is indicated for use as an aid in the treatment of Bovine Respiratory Disease due to Mannheimia haemolytica in cattle 4 months of age or older, when administered at the time of, or within 24 hours after, a perceived stressful event.

IMPORTANT STORAGE CONDITIONS

Store Refrigerated

2°C to 8°C (35°F to 46°F)

DO NOT FREEZE.

STUDY DATA

In Study A, 3- to 4-month-old steers were randomly allocated to receive either ZELNATE™ or a negative control (N=32 per group). On Day 0, each group of healthy calves was intramuscularly administered their respective treatment and challenged (intratracheally) with Mannheimia haemolytica. Lung lesion scores were obtained on Day 5. ZELNATE™ significantly (p<0.05) reduced lung lesion scores compared to the control group (Figure A).1

In Study B, 3- to 4-month-old steers were randomly allocated to receive either ZELNATE™ or a negative control (N=40 per group). On Day 0, each group was challenged (intratracheally) with Mannheimia haemolytica. Twenty four hours post-challenge (i.e., Day 1), BRD morbidity was observed to be 67.5%. At this time, each group was intramuscularly administered their respective treatment (i.e., in the face of clinical BRD). Lung lesion scores were obtained on Day 5. Among calves that lived until Day 5, ZELNATE™ numerically reduced lung lesion scores compared to the control group (data not shown). The cumulative incidence of death, associated with BRD, was 11.3%. The lung lesion scores among dead calves and those living to Day 5 were observed to be 55.3% and 17.6%, respectively. ZELNATE™ significantly (p<0.05) reduced mortality compared to the control group (Figure B).2

Figure A: Average lung lesion scores between calves receiving either ZELNATE™ or a negative control at the same time as an intratracheal Mannheimia haemolytica challenge. Lung lesion scores reflect those observed on Day 5 post-challenge.

Figure B: Cumulative incidence of mortality between calves receiving either ZELNATE™ or a negative control 24 hours after an intratracheal Mannheimia haemolytica challenge. Mortality estimates reflect those observed from the Day of challenge (Day 0) to Day 5 post-challenge.

* = statistically significant reduction (p<0.05)

In conclusion, ZELNATE™, as a stand-alone therapy, has been shown to: 1) significantly reduce lung lesion scores associated with BRD when administered in the face of disease challenge (Study A), and 2) significantly reduce the risk of mortality when administered in the face of clinical BRD (Study B).

1Data on file. Bayer HealthCare Animal Health.

2Data on file. Bayer HealthCare Animal Health.

METHOD OF ADMINISTRATION

Inject 2 mL intramuscularly at the time of, or within 24 hours after, a perceived stressful event (for example: weaning, shipping, commingling or adverse environmental conditions). Use entire contents of vial once first opened.

PRECAUTION

Do not administer within 21 days of slaughter.

OTHER INFORMATION

Contains no antibiotics and no preservatives.

ZELNATE™ has shown no detectable lesions at the site of intramuscular injection.

Mixing process must be completed in the appropriate order. Transfer needle must be fully inserted to prevent spillage.

ZELNATE™ is ready for use.

MANUFACTURED BY:

Diamond Animal Health, Inc., Des Moines, IA 50327

U.S. Veterinary License No. 213

Made in U.S.A.

DISTRIBUTED BY:

Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201 U.S.A.

1-800-633-3796

83944706, R.0 83944722, R.0 83944730, R.0

This product is based on technology developed by Juvaris BioTherapeutics and is patent protected. Animal health applications are being exclusively developed by Bayer HealthCare Animal Health and are protected by Bayer patent applications.

©2014 Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, Kansas 66201 U.S.A.

Bayer (reg’d), the Bayer Cross (reg’d) and ZELNATE™ are trademarks of Bayer.

52405B

Regulations for product use are established by country. Information contained on this site pertains only to the United States of America, and is not intended to provide adequate information for product use. Before using or dispensing any product, read and carefully observe the label directions.

BAYER HEALTHCARE LLC
Animal Health Division

P.O. BOX 390, SHAWNEE MISSION, KS, 66201-0390
Customer Service Tel.:   800-633-3796
Customer Service Fax:   800-344-4219
Website:   www.bayer-ah.com
   
Every effort has been made to ensure the accuracy of the Zelnate information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide